IMRA News and Press, IMARA Inc. From 08/08/21

IMARA Inc. (IMRA) Q2 2021 Earnings Conference Call August 6, 2021 8:30 AM ET Company Participants Mike Gray – Chief Financial and Chief Operating Officer Rahul Ballal – President and Chief Executive Officer Ken Attie – Chief Medical Officer Conference Call Participants Co...

Accelerated enrollment in Phase 2b trials in sickle cell disease and beta-thalassemia; interim analyses expected in fourth quarter of 2021 Positive IMR-687 data in sickle cell disease presented at the European Hematology Association (EHA) Annual Congress HFpEF Phase 2 pr...

Imara (NASDAQ:IMRA) announces that the company has completed patient enrollment in the Ardent Phase 2b clinical trial of IMR-687, a potent small molecule inhibitor of PDE9, for the treatment of sickle cell disease (SCD). The company expects to report data from the primary analysis in the firs...

BOSTON, Aug. 05, 2021 (GLOBE NEWSWIRE) -- Imara Inc. (Nasdaq: IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients suffering from rare inherited genetic disorders of hemoglobin and other serious diseases, today an...

BOSTON, July 30, 2021 (GLOBE NEWSWIRE) -- Imara Inc. (Nasdaq: IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients suffering from rare inherited genetic disorders of hemoglobin, today announced that the company wi...

Gainers: AcelRx Pharmaceuticals ACRX +19%, GBS (GBS) +13%, Navidea Biopharmaceuticals (NAVB) +7%, Cellect Biotechnology (APOP) +6%, Adagene (ADAG) +2%.Losers: Allied Healthcare Products (AHPI) -34%, Allena Pharmaceuticals (ALNA) -31%, SCWorx (WORX)...

Allied Healthcare Products (AHPI) -24%.Glaukos (GKOS) -21% comments on the centers for medicare and medicaid services 2022 proposed physician fee scheduleAllena Pharmaceuticals (ALNA) -20% after launches $28M direct offeringIMARA (IMRA) -15% after secures $50M capital...

Imara (IMRA) has priced its public offering of common shares at $6.00/share, for gross proceeds of $50M.Underwriters' over-allotment is an additional $7.5M of shares.Closing date is July 16.Morgan Stanley, SVB Leerink and Cantor are acting as joint book-running managers for the offering....

BOSTON, July 13, 2021 (GLOBE NEWSWIRE) -- Imara Inc. (the “Company”) (Nasdaq: IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients suffering from rare inherited genetic disorders of hemoglobin, annou...

Imara (IMRA) announces that it has commenced a proposed underwritten public offering of $50M of shares.Intends to grant the underwriters a 30-day option to purchase up to an additional $7.5M of shares.Shares down 11% post market. For further details see: Imara shares slide on $50M ...